Curis (FRA:CUS0) Total Operating Expense: €35.52 Mil (TTM As of Mar. 2026)


FRA:CUS0 Curis Inc FRA:CUS0
51 GF Score
Price €6.12
GF Value €1.30
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Curis Total Operating Expense?

Curis FRA:CUS0 51 Total Operating Expense is €35.52 Mil as of Mar. 2026. GuruFocus rates FRA:CUS0 with a GF Score™ of 51/100 and a GF Value™ of €1.30 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Curis's Total Operating Expense for the three months ended in Mar. 2026 was €9.96 Mil. Curis's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €35.52 Mil.

Curis Total Operating Expense Related Terms

Curis Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Curis's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curis Total Operating Expense Chart

Curis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.18 59.40 53.32 52.86 36.12

Curis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.58 9.52 8.59 7.44 9.96
FRA:CUS0
51GF Score
Curis Inc FRA:CUS0
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curis Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €35.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €35.52 Mil mean?
Curis (FRA:CUS0) has a Total Operating Expense of €35.52 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Curis and its competitors.
Is Curis' Total Operating Expense too high?
Curis' current Total Operating Expense is €35.52 Mil. Overall, Curis has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Curis' Total Operating Expense compare to CALC and ICU?
Curis' Total Operating Expense of €35.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Curis and its competitors. Curis's current Total Operating Expense is €35.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis stock overvalued right now?
Based on GuruFocus' analysis, Curis (FRA:CUS0) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.30, compared to a current price of €6.12 — trading 370.8% above its estimated fair value. The current Total Operating Expense is €35.52 Mil. Curis' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Curis (FRA:CUS0), the current Total Operating Expense is €35.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Curis (FRA:CUS0) Overvalued in 2026?

Based on GuruFocus' analysis, Curis stock appears to be overvalued. The current stock price of €6.12 is trading 370.8% above its estimated GF Value™ of €1.30. GuruFocus considers Curis to be Significantly Overvalued.

Key valuation signals for FRA:CUS0:

  • Total Operating Expense: €35.52 Mil
  • GF Value™: €1.30 vs. price of €6.12 (370.8% above fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the FRA:CUS0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Curis Business Description

Other Exchanges CRIS:USA
Address 128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
51GF Score

Get the complete analysis for FRA:CUS0

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.12
Price
€1.30
GF Value